Experimental cancer drug KZR-261 tested in early trial
NCT ID NCT05047536
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the data collected helps understand how the drug works in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KZR-261
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This was an early, small Phase 1 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, 78229, United States
-
Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville
Nashville, Tennessee, 37203, United States
-
University Hospitals - Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
Virginia Cancer Specialists (VCS)
Fairfax, Virginia, 22031, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States